Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Thomas Cartwright"'
Publikováno v:
International Journal of Abdominal Wall and Hernia Surgery, Vol 6, Iss 1, Pp 44-47 (2023)
In this case report, we discuss an 83-year-old woman who presented to the emergency department with complaints of constipation and progressive abdominal pain 2 days after a right total knee arthroplasty. Chest X-ray indicated a possible hiatal hernia
Externí odkaz:
https://doaj.org/article/15ceeab3680d4f7e87a2123a4d7f489b
Autor:
W. Quinn O’Neill, Xiujie Xie, Shanying Gui, Heping Yu, Jacqueline Davenport, Thomas Cartwright, Marta Storl-Desmond, Esther Ryu, Ernest R. Chan, Shufen Cao, Pingfu Fu, Theodoros N. Teknos, Quintin Pan
Publikováno v:
Cancers; Volume 14; Issue 2; Pages: 282
Cancers, Vol 14, Iss 282, p 282 (2022)
Cancers
Cancers, Vol 14, Iss 282, p 282 (2022)
Cancers
Simple Summary A critical need for optimal management of human papillomavirus-associated head and neck squamous cell carcinoma (HPV+ HNSCC) patients is the development of therapeutic strategies to exploit the inherent vulnerabilities of this unique d
Autor:
Sylvia Hu, Thomas Cartwright, Herbert Hurwitz, Edward McKenna, Ambrose Kwok, Yehuda Z. Patt, Edith P. Mitchell
Publikováno v:
The Oncologist. 17:937-946
Background. Capecitabine administered for 7 days biweekly with oxaliplatin (XELOX) biweekly has been reported to have activity and safety profiles similar to those of standard capecitabine given for 14 days triweekly. Multiple studies have shown that
Autor:
Jordan Berlin, Thomas Cartwright, Fairooz F. Kabbinavar, W. Heim, Frank A. Scappaticci, John D. Hainsworth, Herbert Hurwitz, William Novotny, S. Sarkar, Louis Fehrenbacher
Publikováno v:
Journal of Surgical Oncology. 91:173-180
Background Bevacizumab (Avastin™; rhuMab VEGF), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), significantly prolongs survival when added to intravenous 5-fluorouracil-based chemotherapy in first-line metastatic
Publikováno v:
Pharmaceuticals
Pharmaceuticals; Volume 10; Issue 1; Pages: 19
Pharmaceuticals; Volume 10; Issue 1; Pages: 19
Access to bevacizumab, an important component of oncology treatment regimens, may be limited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets (EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barrier
Autor:
Thomas Cartwright, Bruce F. Waller, Shawn Brennan, James H. Adlam, David L. Patterson, Walter Jolly
Publikováno v:
Clinical Cardiology. 16:741-744
Penetrating atherosclerotic ulcer of the aorta is a rare entity which usually occurs in the descending thoracic aorta. Herein, we report an unusual case of penetrating aortic ulcer which ruptured into the mediastinum. Interscapular back blows were pe
Publikováno v:
Oncology. 77(3-4)
Objective: To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection. Methods: This retrospective, claim-based study utiliz
Autor:
Robert W. Ross, John D. Hainsworth, Herbert Hurwitz, Susan Griffing, W. Heim, Thomas Cartwright, Gwen Fyfe, William Novotny, Ari David Baron, Jordan Berlin, Napoleone Ferrara, Beth Rogers, Louis Fehrenbacher, Fairooz F. Kabbinavar, Eric Holmgren
Publikováno v:
The New England journal of medicine. 350(23)
background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. methods Of 813 patien
Autor:
Frank A. Scappaticci, Louis Fehrenbacher, Thomas Cartwright, John D. Hainsworth, William Heim, Jordan Berlin, Fairooz Kabbinavar, William Novotny, Somnath Sarkar, Herbert Hurwitz
Publikováno v:
Journal of Surgical Oncology; Aug2005, Vol. 91 Issue 3, p173-180, 8p
Autor:
Thomas Cartwright
Publikováno v:
Národní knihovna České republiky.